Global InformationCipaglucosidase alfa information
| Clinical data | |
|---|---|
| Trade names | Pombiliti |
| Other names | ATB-200, ATB200, cipaglucosidase alfa-atga |
| Routes of administration | Intravenous |
| Drug class | Enzyme replacement |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| DrugBank |
|
| UNII |
|
| KEGG |
|
| ChEMBL |
|
| Chemical and physical data | |
| Formula | C4489H6817N1197O1298S32 |
| Molar mass | 99347.92 g·mol−1 |
Cipaglucosidase alfa, sold under the brand name Pombiliti, and used in combination with miglustat, is a medication used for the treatment of glycogen storage disease type II (Pompe disease).[3] Cipaglucosidase alfa is a recombinant human acid α-glucosidase enzyme replacement therapy that provides an exogenous source of acid α-glucosidase.[3]
The most common side effects include chills, dizziness, flushing, sleepiness, chest discomfort, cough, swelling at the infusion site and pain.[3]
Cipaglucosidase alfa was approved for medical use in the European Union in March 2023.[3]
- ^ "Cipaglucosidase alfa with miglustat: Treatment protocol: Information for healthcare professionals". Medicines and Healthcare products Regulatory Agency (MHRA). 8 June 2021. Retrieved 18 December 2022.
- ^ "Cipaglucosidase alfa with miglustat in the treatment of late-onset Pompe disease". Medicines and Healthcare products Regulatory Agency (MHRA). 8 June 2021. Retrieved 17 May 2023.
- ^ a b c d e Cite error: The named reference
Pombiliti EPARwas invoked but never defined (see the help page).